Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management

Cardiovascular outcome trials of glucose-lowering medications: an update

(2019) Philip Home   DIABETOLOGIA

Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists

(2019) Muthiah Vaduganathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

(2018) Kashif M. Munir et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cardiovascular Disease and Diabetic Kidney Disease

(2018) Muhammad Maqbool et al.   SEMINARS IN NEPHROLOGY

Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes Mellitus, 1988–2015

(2018) Yiling J. Cheng et al.   DIABETES CARE

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

(2017) Aidin Rawshani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis

(2016) Jose Miguel Baena-Díez et al.   DIABETES CARE

Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia

(2016) Clifford J. Bailey   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Perceived facilitators and barriers in diabetes care: a qualitative study among health care professionals in the Netherlands

(2013) Lieke GM Raaijmakers et al.   BMC Family Practice

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams

(2008) Tim Hulsen et al.   BMC GENOMICS